mProbe Taiwan Inc.
Update：2025/12/03
Industries
Main Industry
Health Care
Main Product/Service
mProbe is aiding oncologists in making informed clinical decisions by providing more comprehensive tumor profiling. And we can deliver more information with less tissue and in less time. With just 2 slides, our patented process allows us to identify over 70 sensitivity & resistance protein biomarkers and return actionable results in days, not weeks.
Founded Year
2017
Unified Business No.
52703902
Status
Active
Number of Employees
0
Total Paid-in
Capital
48,500,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
mProbe believes that the future is personalized medicine. Only by fully understanding the biology of a patient’s cancer can you determine the optimal treatment for that patient and, more to the point, their unique cancer. When an oncologist has access to proteomic and genomic data from FFPE tissue samples, they receive an additional and invaluable profile of the cancer at the molecular level. This allows the doctor to tailor the treatment directly to the cancer.
